PSMA expression in differentiated thyroid cancer: association with radioiodine, 18FDG uptake, and patient outcome.

Context Little is known about prostate-specific membrane antigen (PSMA) expression in patients with cervical involvement of differentiated thyroid cancer (DTC). Objective We investigated PSMA expression in neck persistent/recurrent disease (PRD) using immunohistochemistry and the association with radioiodine (RAI) or 18Fluorodeoxyglucose ( 18FDG) uptake, and patient outcome. Design, setting and patients Data from 44 consecutive DTC patients who underwent neck reoperation from 2006 to 2018 in a comprehensive cancer center. Main outcome measure(s) Immunostaining was performed with vascular endothelial marker CD31 and PSMA. PSMA expression was quantified using the immunoreactive score (IRS). RAI and 18FDG uptake were assessed before surgery using post-therapeutic RAI scintigraphy and 18FDG PET/CT. Mean follow-up after re-intervention was 6.5 ±3.7 years. Results Thirty patients (68%) showed at least one PSMA-positive lesion (IRS≥2) with similar proportions in RAI-positive and RAI-negative patients (75% vs. 66%). In RAI-negative patients, however, the proportion of PSMA-positive disease (79% vs. 25%, p 40 mm) or aggressive subtypes, and was correlated with structural disease at last follow-up. Strong PSMA expression (IRS≥9) was associated with shorter progression-free survival (PFS). Conclusions Our findings show that PSMA expression was present in two-thirds of patients with neck PRD, that it was related to poor prognostic factors and that very high expression was associated with poorer PFS. This preliminary study may offer new perspectives for the management of RAI-refractory DTC.